ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
ACS Global Inc (CE)

ACS Global Inc (CE) (AMCY)

3.00
0.00
( 0.00% )
Updated: 20:00:00

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
3.00
Bid
0.00
Ask
0.00
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
3.00
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

AMCY Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
156-1-25450.752671.82078008CS
2602.4899488.1199764750.5101290.455382.49352962CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GRDIGRIID Infrastructure Inc
$ 1.47
(162.50%)
142.98M
ZAPPZapp Electric Vehicles Group Ltd
$ 2.9301
(115.45%)
87.38M
MGOLMGO Global Inc
$ 0.7699
(67.95%)
153.47M
RELIReliance Global Group Inc
$ 0.587
(50.09%)
125.24M
MOLNMolecular Partners AG
$ 10.8263
(36.01%)
319.65k
WHLRWheeler Real Estate Investment Trust Inc
$ 2.72
(-82.70%)
149.09k
KAVLKaival Brands Innovations Group Inc
$ 2.7401
(-39.11%)
1.05M
MBIOMustang Bio Inc
$ 0.559955
(-34.13%)
35.79M
SONNSonnet BioTherapeutics Holdings Inc
$ 1.03
(-32.68%)
343.79k
TRVNTrevena Inc
$ 0.2401
(-32.25%)
37.3M
NVDANVIDIA Corporation
$ 131.79
(-2.80%)
407.05M
NKLANikola Corporation
$ 0.34019
(-29.26%)
224.5M
SMXSMX Security Matters Public Company
$ 0.1512
(27.06%)
168.06M
MGOLMGO Global Inc
$ 0.7699
(67.95%)
153.47M
GRDIGRIID Infrastructure Inc
$ 1.47
(162.50%)
142.98M

AMCY Discussion

View Posts
Stockmater Stockmater 3 years ago
I am still surprised AMCY hasn't gone up with that float and multiple mentions in filings for both companies. Float is only 40,049 and has been for years.
πŸ‘οΈ0
StockLogistics StockLogistics 3 years ago
β€œParlor trick: as the 20,000,000 β€œretired shares” bought back from AMCY are only cancelled till November 11,2022 when AMCY can convert its series A shares back into 20,000,000 common shares of CRYO, call it a temporary retirement or shares to dilute this increase to pay for its operations for one year, PR was full of fluff, would take a long time to see progress from whatever it was projecting, they have to pay AMCY 200,000 a quarter for 4 quarters as part of the deal as well, all imo
”

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166834619
πŸ‘οΈ0
Stockmater Stockmater 5 years ago
FLOAT - 40,049
πŸ‘οΈ0
Stockmater Stockmater 5 years ago
Any current shareholders still active?
πŸ‘οΈ0
Stockmater Stockmater 5 years ago
Needs new box information. Going to try and write that up today.
πŸ‘οΈ0
Stockmater Stockmater 5 years ago
AMCY – ACS Global Inc.
188 East Bergen Place
Suite 204
Red Bank, NJ 07701
http://www.americancryostem.com/
732-747-1007
info@americancryostem.com

As of February 8, 2019:
100,000,000 Authorized Common Shares
57,160,416 Total Outstanding Common Shares
57,120,367 Total Restricted Common Shares
40,049 Total Float Common Shares

Upon closing of an asset purchase on April 20, 2011, ACS Global became the majority shareholder of CRYO - American Cryostem Corp acquiring 21,000,000 shares of their common stock.
πŸ‘οΈ0
Stockmater Stockmater 5 years ago
Are you still holding shares here?
πŸ‘οΈ0
biotechfunder biotechfunder 13 years ago
Lots of misinformation in ibox AMCY is now majority shareholder of CRYO.ob
πŸ‘οΈ0
$hellKing $hellKing 13 years ago
Ok thats what I was getting out of it. trying to digest it. Away from home in a noisy household.lol


Well Both should go up I would imagine. I like OTCQB's better but I would imagine AMCY is going to go otcqb.
πŸ‘οΈ0
nosecret nosecret 13 years ago
2 different companies and:
About ACS Global, Inc. : ACS Global, Inc. is the controlling shareholder of American CryoStem Corporation, and develops new technologies internally and through strategic relationships in the rapidly developing regenerative medicine and stem cell industry.
---> amcy is controlling shareholder of cryo (former rapp)
πŸ‘οΈ0
$hellKing $hellKing 13 years ago
So they are going to be 2 diff cos? Or AMCY is like a holding co?
πŸ‘οΈ0
nosecret nosecret 13 years ago
no the CRYO is the old RAPP
AMCY symbol stays the same but name change to ACS Global
13:56 6/15/2011 AMCY American Cryostem Corporation Common Stock AMCY ACS Global, Inc. Common Stock **

13:56 6/15/2011 RAPP R & A Productions, Inc. Common CRYO American Cryostem Corporation. Common **
http://otcbb.com/asp/dailylist_detail.asp?d=06/14/2011&mkt_ctg=ALL
(scroll down)
πŸ‘οΈ0
$hellKing $hellKing 13 years ago
So the two symbols merge? I got to check my account.
πŸ‘οΈ0
nosecret nosecret 13 years ago
Wednesday, June 15 2011 9:00 AM, EST American CryoStem Corporation Announces Name Change to ACS Global, Inc. Marketwire   "Press Releases"


RED BANK, NJ -- (MARKET WIRE) -- 06/15/11 -- American CryoStem Corporation (PINKSHEETS: AMCY) announced today that at the open of business June 15, 2011 , the name change of American CryoStem Corporation to ACS Global, Inc. will take effect. The Company will retain its current symbol AMCY.PK.

Mr. Anthony Dudzinski , CEO, stated, "We are excited to complete this name change as the final step in our transaction with R & A Productions, Inc. ACS Global will continue to explore opportunities globally to secure and expand its position within the stem cell and regenerative medicine industry."

About ACS Global, Inc. : ACS Global, Inc. is the controlling shareholder of American CryoStem Corporation, and develops new technologies internally and through strategic relationships in the rapidly developing regenerative medicine and stem cell industry.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company's reports filed with the Securities and Exchange Commission .

For More Information, contact: Investor Relations American CryoStem Corporation 188 East Bergen Place , Suite 204 Red Bank, NJ 07701 Phone:732-747-1007 Fax: 732-747-7782 www.americancryostem.com

Source: American CryoStem
πŸ‘οΈ0
biotechfunder biotechfunder 13 years ago
http://investorshub.advfn.com/boards/board.aspx?board_id=21062
πŸ‘οΈ0
$hellKing $hellKing 13 years ago
Are they just going to merge the 2 together?

Thursday, April 28 2011 5:27 PM, EST American CryoStem Announces Asset Sale Marketwire   "Press Releases"
RED BANK, NJ -- (MARKET WIRE) -- 04/28/11 -- American CryoStem Corporation (PINKSHEETS: AMCY) announced today that on April 20, 2011 R & A Productions, Inc. (OTCBB: RAPP) purchased substantially all of the assets from, and assumed substantially all of the liabilities of, AMCY in exchange for the issuance by RAPP to AMCY of 21,000,000 shares of RAPP's restricted common stock, resulting in AMCY becoming the majority shareholder of RAPP. Contemporaneously with the asset purchase closing, RAPP sold, in a private placement made solely to accredited investors, 1,860,000 shares of its restricted common stock for gross proceeds of $930,000 .

Mr. Anthony Dudzinski , the CEO of AMCY, stated, "Because RAPP is a publicly traded reporting company, we believe that the sale of AMCY's assets to RAPP for 21,000,000 shares of RAPP common stock will enhance our shareholders' value."

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors including, but not limited to, the stem cell industry, RAPP's stock price and trading volume, general economic conditions, RAPP's business success and or failure, and its continued development of the assets it acquired from AMCY, the financial position of RAPP and RAPP's ability to successfully commercialize the business it acquired from AMCY when it acquired AMCY's assets.

For More Information, contact: Investor Relations American CryoStem Corporation 188 East Bergen Place , Suite 204 Red Bank, NJ 07701 Phone: 732-747-1007 Fax: 732-747-7782 www.americancryostem.com

Source: American CryoStem Corporation
πŸ‘οΈ0
$hellKing $hellKing 13 years ago
Maybe you will get shares? Keeps mentioning AMCY....

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=7562837
πŸ‘οΈ0
$hellKing $hellKing 13 years ago
Thats what Im thinking. They changed their mind on the pink shell. I had it happen with another stock I was in. They had a pink RM and soon after it went grey so they just bought another one and used it right after.


I got some RAPP already so hoping it will do a FS or something.
πŸ‘οΈ0
biotechfunder biotechfunder 13 years ago
How do the boards work in this case? Will this board get deleted? I guess the new board should be the RAPP one and then it should automatically switch the board name when the name change happens. I'm guessing
πŸ‘οΈ0
biotechfunder biotechfunder 13 years ago
Its getting harder and harder with the SEC to do anything with a shell that has been quite to long and on the pinks looks like RAPP will serve as the vehicle for AMCY to be a reporting company as per the press release.
πŸ‘οΈ0
biotechfunder biotechfunder 13 years ago
Figure a few weeks when the transaction takes place for the name changes and symbols.
πŸ‘οΈ0
$hellKing $hellKing 13 years ago
Well I have seen this once before and they just let the old shell go that time. It just looks like they tried to use this one and didnt like it and just grabbed another shell. But I could be wrong.
πŸ‘οΈ0
nosecret nosecret 13 years ago
not sure how to read this:
American CryoStem Corporation (PINKSHEETS: AMCY) announced today that it has entered into an agreement to sell all of its assets to R&A Productions, Inc. in exchange for a controlling interest in R&A Productions, Inc.
will amcy shareholders get rapp (i.e. divi?)
πŸ‘οΈ0
$hellKing $hellKing 13 years ago
Looks like they didnt like this shell and are moving everything to a new shell. Must of been dirty or too hard to do the filings. Now going to be RAPP on the OTCQB.
πŸ‘οΈ0
nosecret nosecret 13 years ago
Thursday, March 24 2011 4:01 PM, EST American CryoStem Announces Asset Sale Marketwire   "Press Releases"
RED BANK, NJ -- (MARKET WIRE) -- 03/24/11 -- American CryoStem Corporation (PINKSHEETS: AMCY) announced today that it has entered into an agreement to sell all of its assets to R&A Productions, Inc. in exchange for a controlling interest in R&A Productions, Inc. The transaction is subject, among other conditions, to the completion of due diligence by both companies.

About American CryoStem : American CryoStem Corporation (PINKSHEETS: AMCY) has developed and markets, a proprietary core processing platform for Adipose (fat) Derived Adult Stem Cells. The Company is in the business of collecting, processing, and long term storage of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in cell therapy at an affordable price. Adult Stem Cells are currently being used in the emerging field of regenerative medicine to potentially heal over an estimated 100+ diseases and chronic conditions. Our proprietary platform provides a streamlined and affordable method to process and cryopreserve Adipose Tissue and Adipose Derived Stem Cells (ADSC) for autologous (self) use in humans.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company's reports filed with the Securities and Exchange Commission .

For More Information, contact: Investor Relations American CryoStem Corporation 188 East Bergen Place , Suite 204 Red Bank, NJ 07701 Phone: 732-747-1007 Fax: 732-747-7782 www.americancryostem.com Email Contact

Source: American CryoStem Corporation
πŸ‘οΈ0
biotechfunder biotechfunder 16 years ago
ibox needs an updating
πŸ‘οΈ0
CashFXGroupPowerTeam CashFXGroupPowerTeam 17 years ago
AWT to Buy New Jersey Company
Company Sets Sale Terms to Closing Documents
Dec 11, 2007 8:45:00 AM
SOMERSET, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Somerset-based AWT, Inc. (OTC: AWTM) today announced that it has agreed to sale terms of its first acquisition target. The transaction includes a cash payment upon transfer of ownership.

The company said it will finance the deal with cash-on-hand.

AWT expects to accept final transfer of ownership of the company at the beginning of 2008. The deal "will provide AWT with a solid footing for 2008 and a cash flow positive asset to continue to build upon," Christopher J. Neill, chief executive officer of the company, said in a statement.

The healthcare supplier projects this asset should grow to approximately $700,000 in revenue and $266,000 for income in 2008. "The owner has been running his business for nearly 20 years and is now retiring. We wish him well. The overall operation we are acquiring has been small for many years, but we plan to change that. With our revenue model in place the purchasing efficiency alone will substantially increase our overall income margins," stated Neill.

Under the agreements, both companies are unable to speak directly regarding the specific terms prior to the closing of the acquisition.

ABOUT AWT, INC.

AWT Inc, headquartered in Somerset, New Jersey, with locations in the USA and Saudi Arabia, is a rapidly expanding durable medical equipment and supply company. It distributes state-of-the-art medical equipment to the healthcare industry, as well as general supplies.

AWT Inc is committed to a more traditional personal service commitment to healthcare and cost efficiencies for clients, providing superior service and products to the healthcare world at the lowest possible price and with delivery times superior to any in the industry. It is equally committed to always exceeding customer expectations and to increasing shareholder value.

Disclaimer:

CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS

The stated terms for the acquisition described in this press release have not been completed for AWTM at the time of writing. It is the intention of AWTM to work with target on an open and direct basis to receive the best value for the asset contemplated and to complete any additional financings contemplated on a best efforts basis and at its earliest possible opportunity. If the acquisition is not completed or any potential financing is not completed, no assurances as to the financial viability of the company can be given. No guarantee can be made by the company as to if the acquisition or potential financing mentioned herein will actually take place and close. If the acquisition and or financing does not close where AWTM has not received assets and or monies for future growth, actual results could differ materially from those projected in the forward-looking statements. This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook.

SOURCE AWT, Inc.



----------------------------------------------
Christopher J. Neill of AWT
Inc. +1-732-246-2330
πŸ‘οΈ0
CashFXGroupPowerTeam CashFXGroupPowerTeam 17 years ago
Time to add some cheap shares next week.
πŸ‘οΈ0
CashFXGroupPowerTeam CashFXGroupPowerTeam 17 years ago

AWT Signs Agreement with Medical Equipment Distribution Company
Acquisition target agrees to acquisition terms with AWT

SOMERSET, N.J., Nov. 27 /PRNewswire-FirstCall/ -- AWT, Inc. (Pink Sheets: AWTM), announced that it has signed agreements that will facilitate its acquisition of a local medical supply and medical equipment distribution company.

The Standstill Agreement allows for AWT and its acquisition partner to continue with business as usual and complete the necessary documents for the closing of the transaction and the financing earlier announced. 'A Standstill Agreement, as both of our companies have agreed, is mutually binding in the fact that we do not go around each other to clients and we do not shop the terms of this deal to rivals. It gives both companies the ability to complete and close the transaction,' commented Christopher J. Neill, AWT's CEO. Furthering his comment, 'Both companies are interested in a smooth transition to a larger organization and resourceful expansion.'

The target company is a New Jersey-based medical equipment distributor and general medical supply company which provides capital equipment to acute care and long term care facilities.

The purchase price to be paid will be a combination of cash and restricted shares of AWT common stock subject to registration rights. The number of AWT shares has been determined, and additional contracts for Earnout have been discussed based on AWT's share price on the one year anniversary of the closing date. Closing of the acquisition is anticipated to occur by year end to early January.

Under the agreements, both companies are unable speak directly regarding the specific terms prior to the closing of the acquisition.

ABOUT AWT, INC.

AWT Inc, headquartered in Somerset, New Jersey, with locations in the USA and Saudi Arabia, is a rapidly expanding durable medical equipment and supply company. It distributes state-of-the-art medical equipment to the healthcare industry, as well as general supplies.

AWT Inc is committed to a more traditional personal service commitment to healthcare and cost efficiencies for clients, providing superior service and products to the healthcare world at the lowest possible price and with delivery times superior to any in the industry. It is equally committed to always exceeding customer expectations and to increasing shareholder value.

Disclaimer:

CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS

The business consulting and strategic consulting services described in this press release have not been completed for AWTM at the time of writing. The agreement also allows for WSE to assist in financing to be raised on a best efforts basis. It is the intention of AWTM to work with WSE on an open and direct basis so as to receive the best value for the consulting offered and to complete any financings contemplated on a best efforts basis and at its earliest possible opportunity. If the consulting services are not completed or any potential financing is not completed, no assurances as to the financial viability of the company can be given. No guarantee can be made by the company as to if the financing mentioned herein will actually take place and close. If the financing does not close where AWTM has not received monies for future growth, actual results could differ materially from those projected in the forward looking statements. This press release contains 'forward-looking statements,' which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks' or 'will.' Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook.

CONTACT:

Investor Relations Contact: AWT, Inc.
Smallcapvoice.com Christopher J. Neill,
Stuart Smith CEO
Managing Director (732) 246-2330
Phone: (512) 267-2430

SOURCE AWT, Inc.

Source: PR Newswire (November 27, 2007 - 8:32 AM EST)

News by QuoteMedia
www.quotemedia.com
πŸ‘οΈ0
CashFXGroupPowerTeam CashFXGroupPowerTeam 17 years ago
Time to add while its under .10 :)
πŸ‘οΈ0
CashFXGroupPowerTeam CashFXGroupPowerTeam 17 years ago
Time to add stock down here, it shouldnn't take much for it to get back to the .20's :)
πŸ‘οΈ0
CashFXGroupPowerTeam CashFXGroupPowerTeam 17 years ago
AWT Signs Agreement with Arizona-Based Consulting Firm
World Stock Exchange agrees to provide consulting and investor relations services for 2008
Nov 8, 2007 10:39:00 AM
SOMERSET, N.J., Nov. 8 /PRNewswire-FirstCall/ -- AWT, Inc. (Pink Sheets: AWTM), announced that it has signed agreements with World Stock Exchange, LLC for business and strategic consulting services.

World Stock Exchange offers a full compliment of consulting services through an extensive network of consummate professionals and successful corporate executives. "Our multi-stage strategy for growth and expansion requires us to have one of two things, a greater executive infrastructure or a subcontractor that can assist us on an effective and best-cost basis," commented Christopher J. Neill, CEO. "The business consulting and strategic consulting offered by WSE should not only bring the additional executive personnel we require but assist us in accelerating our growth. We believe the next year of working with WSE will greatly benefit the company and its stakeholders," he further commented.

The consulting agreement allows for World Stock Exchange to assist in the locating and securing of future financings. "From almost the very first day of our agreement, we have received input about AWT and ideas that can be implemented to aid the company's progress. We are now, receiving requests from several WSE contacts interested in taking part in the multi-million dollar financing we are initiating in by years end," stated Neill.

World Stock Exchange is a paid consultancy and advertiser of companies needing assistance in corporate expansion, investor relations and financings. With over 20 years of experience and success in handling public companies, WSE focuses on emerging, small-cap company's.

ABOUT AWT INC

AWT Inc, headquartered in Somerset, New Jersey, with locations in the USA and Saudi Arabia, is a rapidly expanding durable medical equipment and supply company. It distributes state-of-the-art medical equipment to the healthcare industry, as well as general supplies.

AWT Inc is committed to a more traditional personal service commitment to healthcare and cost efficiencies for clients, providing superior service and products to the healthcare world at the lowest possible price and with delivery times superior to any in the industry. It is equally committed to always exceeding customer expectations and to increasing shareholder value.

Disclaimer:

CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS

The business consulting and strategic consulting services described in this press release have not been completed for AWTM at the time of writing. The agreement also allows for WSE to assist in financing to be raised on a best efforts basis. It is the intention of AWTM to work with WSE on an open and direct basis so as to receive the best value for the consulting offered and to complete any financings contemplated on a best efforts basis and at its earliest possible opportunity. If the consulting services are not completed or any potential financing is not completed, no assurances as to the financial viability of the company can be given. No guarantee can be made by the company as to if the financing mentioned herein will actually take place and close. If the financing does not close where AWTM has not received monies for future growth, actual results could differ materially from those projected in the forward looking statements. This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook.


CONTACT:

Investor Relations Contact:
Smallcapvoice.com
Stuart Smith
Managing Director
Phone: (512) 267-2430
SOURCE AWT, Inc.



----------------------------------------------
Christopher J. Neill of AWT
Inc.
Info@awtmid.com; or Investor Relations Contact
Stuart Smith
Managing Director of Smallcapvoice.com for AWT
Inc.
+1-512-267-2430
πŸ‘οΈ0
CashFXGroupPowerTeam CashFXGroupPowerTeam 17 years ago
Volume is getting stronger day by day :)
πŸ‘οΈ0
CashFXGroupPowerTeam CashFXGroupPowerTeam 17 years ago
Advanced Wound Technologies-MidAtlantic, Inc.
Advanced Wound Technologies-MidAtlantic, Inc. “AWT” the “Company” has been created to take advantage of the thriving Durable Medical Equipment ( “DME” ) market.

Mission Statement
“Secure marketing, distribution and supply rights to patented medical technology, create treatment protocols using additional related products and market those protocols to healthcare providers as solutions to regulatory requirements or to increase efficiency and/or help the provider earn “Quality of Care” incentive bonuses from reimbursement sources.”

Overview
National health care spending for 2001 topped $1.42 trillion; in 2005 it hit $1.7 trillion and health threats continued to rise. By the end of 2006, spending reportedly topped-out at just under $2.1 trillion, a number that was originally projected for the close of 2007. With an ever increasing and aging population (15,000 people turn 65 every day as of January 1, 2005) the United States cannot effectively address escalating health care costs without investing in public health programs that reduce these costs through prevention, control and treatment of disease and injury. (2005 Healthcare Overview (multiple articles), CMS, HHS)

Original analysis (2001 Healthcare overview (multiple articles), CMS, HHS) said that by 2024, $.38 of every dollar would be used for healthcare costs. Most financial analysts and economists would consider these numbers from a bankrupt position if looking at it as a corporation. From 2001, when most analysis was compiled through CMS and private corporations, this represents a growth rate in healthcare costs of approximately 12% year over increase. As of 2002, expenditure growth rate has averaged 16% year over increases and with an ever increasing and aging population. These excited cost increases are expected to continue for the foreseeable future. (Center for Medicare & Medicaid)

Aside from the common increases in public health investment, one area that has shown dramatic results not only in better quality healthcare but the potential to dramatically decrease overall costs is the proper implementation of the most advanced, state-of-the-art medical device and medical capital equipment for healthcare.

Bringing together well rounded, properly implemented technology that can be associated with more than one “incident” in healthcare, will decrease the cost of treatment, especially if it is put into practice as preventative measure.



The Market

Wound care concerns
The ability to clinically prevent, and of course cure, specific “incidents” from occurring in healthcare means an immediate cost savings for that specific event. An “incident” such as the appearance of decubitus ulcers on a patient during an acute care stay-a nosocomial event, could save as much as $50,000 for the facility of out of pocket expense to cure what was to never have occurred. With 1.7 million patients in 2006 treated with severe decubiti events, up from 1.1 million in 2004 (an increase of 54.5%), it is easy to say one of the core issues involved here is an ever increasing “incident rate”.

Unfortunately we cannot stop with the “incident rate”; we must accept the cross incident rates now being documented between diseases and realize our issues are compounding. Bariatric, Pulmonary, Diabetic, Ostomy, Spinal Cord Injury, Burn victims, these are all issues now being directly confronted in wound care. Proper handling of these diseases, injuries and “incidents” with specific treatment protocols, and with state-of-the-art medical device and equipment, will bring down the overall cost of treatment, if handled properly.


Spinal Cord Injury
Bedridden patients are typically in long-term care facilities, home care settings, and in certain instances acute care settings. Spinal cord injured individuals are essentially wheelchair bound. The prolonged immobilization of these individuals causes constant interface pressure on the areas of skin overlying what are called the bony prominences. More specifically, these areas include the sacrum (upper buttock area), ischial tuberosities (hamstring and lower buttock area), trochanters (hip/pelvic area), heels and latter malleoli (shoulder blade/scapula area). Studies have shown that 95% of all pressure ulcers develop in the lower portion of the body. Relieving these interface pressures while an individual is in a seated position has always posed a technological challenge. It is a challenge that AWT believes the technology it offers has met.

The numbers of people in the U.S. alive today who have spinal cord injury (SCI) has been estimated to be 247,000 with a range between 222,000 and 285,000 individuals. Every year, approximately 11,000 people sustain new spinal cord injuries – that’s thirty new injuries every day. Most of these people are injured in auto and sports accidents, falls, and industrial mishaps. An estimated 60 percent of these individuals are 30 years old or younger, and the majority of them are men (The National Spinal Cord Injury Association, 2005). Pressure sore development is the #2 cause for unplanned re-hospitalization among SCI patients. 89% of SCI patients are cared for in a home health care setting in the first year following injury and this percent increases as years pass. Continuity of care is essential to the treatment and prevention of pressure sores in this environment to minimize re-hospitalization. Allowing pressure ulcers to heal while a patient is sitting has always been a challenge to healthcare professionals.

Part of our product offering will allow for continuity of care between a bed and seating position. This level of care should decrease the occurrence and severity of pressure ulcers for SCI patients and should alleviate the added burden of cost associated with reoccurrence of decubiti.

Decubitus Ulcer/Pressure sore/Bed sore
Conservatively, the cost of healing decubitus ulcers (pressure ulcers or bed sores) surpassed $55 billion annually (Decubitus Foundation-2004). Additionally, the cost of litigation associated with decubitus ulcers annually, the number one source of malpractice and negligence litigation in the long term care market has additionally surpassed $165 billion (American Health Lawyers Association-2005). This problem is magnified to the healthcare facility because in many cases a pressure ulcer that appears after admission, is blamed on the healthcare provider by the reimbursement groups who the refuse to pay for the treatment and cure of the decubitus ulcer. The cost to a healthcare facility to cure one single class 3 or class 4 pressures sore can exceed $50,000. Pressure ulcers typically form from within and can begin after a minimal amount of time (as little as four hours) spent immobilized, or in bed, but will not appear on the surface for as long as 7 to 14 days. This long development cycle is why many long-term health care facilities are blamed for their occurrence and are forced to cover the cost of treatment and cure of pressure sores without the aid of reimbursement. This is also the basis for recent changes in the protocols and guidelines concerning the screening of patients for their susceptibility to pressure ulcers.

Diabetes
Diabetes mellitus, commonly referred to as diabetes, is a disorder in which the levels of sugar (also called glucose) in the blood are elevated because of problems related to insulin. Insulin is a hormone produced by the pancreas that helps the body maintain appropriate blood sugar levels. Insulin enables blood sugar to be transferred into cells. Once inside the cells, sugar is converted to energy, which is either used immediately or is stored until needed. In patients with diabetes mellitus, the levels of sugar in the blood are too high because not enough insulin is produced (type 1 diabetes) or the body becomes resistant to insulin (type 2 diabetes). With both types of diabetes, blood sugar is unable to enter the cells to provide the fuel needed to function properly, leading to problems with basic metabolism of the cells and the body as a whole.
Diabetes is a chronic disease that has no cure. There are an estimated 20.8 million children and adults in the United States, or 7% of the population, who have diabetes. While an estimated 14.6 million have been diagnosed, unfortunately, 6.2 million people are not aware that they have the disease. 54 million people have pre-diabetes.
Many people with diabetes eventually become inert because of pain, dysfunction or simply the inability to handle the serious and sometimes painful associated comorbid complications. The most prevalent and serious of these complications being Diabetic (Neuropathic) Ulcers, Heart Disease and Stroke, High Blood Pressure, Kidney Disease, Nervous System Damage, and Amputations. Because of the high comorbid rates associated with diabetes a more focused division may be formed and capitalized to handle the disease. Diabetes is the fifth-deadliest disease in the United States. Since 1987 the death rate due to diabetes has increased by 45 percent, while the death rates due to heart disease, stroke, and cancer have declined.
Based on death certificate data, diabetes contributed to 224,092 deaths in 2002. Studies indicate that diabetes is generally under-reported on death certificates, particularly in the cases of older persons with multiples chronic conditions such as heart disease and hypertension. Because of this, the toll of diabetes is believed to be much higher than officially reported. (American Diabetes Association, HHS, CMS)



Advanced Wound Technologies is continually investigating and researching additional medical devices and equipment for the treatment and prevention of decubitus ulcers (bedsores) and the treatment of post surgical wounds and burn victims. Additional treatment protocols for Bariatric patients, pulmonary patients as well as “cross incident occurrence” associated with these issues will be researched and if monetarily viable, will be produced. These products will be added to the companies’ product offerings so as to create an overall “wound care protocol” that is, more efficient and cost effective, and, potentially lowers the risk of regulatory and legal liability of, the healthcare provider. These protocols and patented products will be supplied to Hospitals, Long-term care facilities, Rehabilitation facilities, Nursing Homes, Extended Care Facilities, Hospices, and individually to home patients that require special care.

AWT will produce research and industry white papers associated with the expansion of clinical applications for the AWT family of products and protocols.






Target Markets

The AWT marketing strategy enhances, promotes and supports the fact that the state-of-the-art technologies it supplies are more versatile, therapeutic and price competitive than lesser or similar existing products. The Company's present overall marketing plan targets the following health care providers:


Number of Facilities
Skilled Nursing Facilities 17,768
General & Medical Hospitals 10,337
Home Health Care Providers 19,212
HMO’s and Managed Care Networks 275

Specialized medical equipment is typically ordered and reimbursed with a doctors prescription and a certification of need for the patient.

Although the ultimate end users of specialty support surfaces are bedridden and wheelchair bound patients these patients are not ordinarily or necessarily considered the customers. Medicare and private insurance reimbursement are the primary reimbursement and funding sources, for these types of support surfaces and treatments, in health care facilities and home care settings. With Medicare’s Home Health Prospective Payment System (PPS), health care cost containment and optimal clinical outcomes are directly related. Offering the low cost and best surface solution for bedsore treatment and avoidance is one of the opportunities at hand.

In clinical settings, PPS fixes a per diem payment for patient care that ranges from $154 to $320. The reality of having to manage all of the patient care, including ancillaries such as our support surfaces, within these financial parameters is significant. These facilities can no longer afford the exposure to the significant costs of secondary complications such as pressure sores and have begun to view specialty beds as assets with which they can better administer patient care and mitigate secondary liability. This is significant in light of the recent CMS Regulations and Guidance.

Skilled Nursing Facilities are long term care facilities primarily engaged in providing inpatient nursing and rehabilitative services to patients who require continuous health care, but not hospital services. Care must be ordered by and under the direction of a physician. The staff must include a licensed nurse on duty continuously with a minimum of one full-time registered nurse on duty during each day shift.


Estimated Number of U.S. Facilities 17,768
Number of people employed in this segment 1,650,884
Annual Revenues in this Segment $196.9 billion
Average Employees per Facility 106
Average Revenues per Facility $11.0 million



General Medical and Surgical Hospitals are establishments primarily engaged in providing general acute medical and surgical services and other hospital services.

Estimated number of U.S. facilities 10,337
Number of people employed in this segment 4,293,465
Annual revenue in this segment $385.6 billion
Average employees per facility 522
Average revenue per facility $738.7 million

Home Health Care Services include firms primarily engaged in providing skilled nursing or medical care in the home, under supervision of a physician.





Estimated Number of U.S. Firms 19,212
Number of people employed in this segment 709,375
Annual Revenues in this segment $188.6 billion
Average Employees per Firm 48
Average Revenues per Firm $9.8 million




Medicare Part “B” reimburses for specialty beds in home-health-care settings for what is considered curative care. Accessing the various providers of clinical services in these settings, such as HMO's and Primary Care Physician groups, affords us an opportunity to provide the low cost/best solution preventative measure for bedsore avoidance.

Hospital and Medical Service Plans and Medicare HMO's are firms engaged in providing hospital, medical, and other health services to subscribers or members in accordance with prearranged agreements or service plans, generally in return for specified subscription charges. The plans may be through a contract with a participating hospital or physician. There are 275 Medicare HMO's Throughout the United States. These plans are continuously seeking the best care at the best price and are expanding their practice of signing fixed rate reimbursement contracts for healthcare products to better predict their expenses and exposure to identifiable healthcare problems. This trend is accelerating in connection with medical treatments and products that can prevent costly clinical conditions, such as pressure ulcers, from occurring. This trend compliments greatly our “cross incident occurrence” initiative that will bring together multiple “incidents” under individual device or equipment. As there are no known treatment protocols to exist presently for wound care device and equipment, much research, studies and trials will be necessary for their creation. We are presently speaking with specialists in healthcare for the first phase of research.

The health services industry is a diverse array of facilities and personnel primarily engaged in furnishing medical, surgical and other health services to people. The specific market segments and their size are highlighted below to provide a better understanding of the size of the market and, because it is primarily in these settings that the support surface products are utilized.

DISTRIBUTION & MARKETING

New opportunities for the distribution of innovative medical equipment technologies are contained in recent government regulatory changes that require Medicare participants to provide a higher standard of care.

Contained within the CMS Manual System (Department of Health and Human Services-Centers for Medicare and Medicaid Services (CMS), Pub 100-07 State Operations Provider Certification, November 12, 2004, Guidance to Surveyors for Long Term Care Facilities (Full Text attached in Appendix B)), are specific requirements stating:

• §483.25 Quality of Care.
“Each resident must receive and the facility must provide the necessary care and services to attain or maintain the highest practicable physical, mental, and psychosocial well-being, in accordance with the comprehensive assessment and plan of care”

• §483.25(c) Pressure Sores
“Based on the Comprehensive Assessment of a resident, the facility must ensure that-
(1) A resident who enters the facility without pressure sores does not develop pressure sores unless the individual’s clinical condition demonstrates that they were unavoidable;
Intent: (F314) 42 CFR 483.25(c)
The intent of this requirement is that the resident does not develop pressure ulcers unless clinically unavoidable and that the facility provides care and services to:
• Promote the prevention of pressure ulcer development;
• Promote the healing of pressure ulcers that are present (including prevention of
infection to the extent possible); and
• Prevent development of additional pressure ulcers.
NOTE: Although the regulatory language refers to pressure sores, the nomenclature widely accepted presently refers to pressure ulcers, and the guidance provided in this document will refer to pressure ulcers.’

Potential performance incentives as defined in Medicare’s “Pay for Performance (P4P) Initiatives (January 31, 2005, CMS, HHS).” further support the introduction of technologies based solutions for “Quality of Care” requirements by offering Medicare providers with end of year bonus incentives for the efficient adoption of sponsored guidelines and regulations.

In addition to supplying the Company’s products directly to Healthcare Facilities, it will utilize healthcare industry Conventions, Trade Shows, Journals, and Seminars in conjunction with Direct Marketing to Wound Care and Operating Room Nurses, Visiting Nursing Associations, Podiatrists, Spinal Cord and Orthopedic Physicians, Wound Care Physicians, Cardiac and Plastic Surgeon Specialists, Burn units (specialties or hospitals) and Anesthesiologists, to name a few specialty fields, to generate interest and understanding of the patients benefits through the use of specialized products and protocols. This strategy will produce qualified sales leads for both our internal and independent sales associates. Direct contact strategies will be employed with National and Regional Institutional sales targets that will be assigned to our national and regional sales associates.

AWT is positioning itself to leverage this convergence of regulation and incentive with the most advanced technologies available in medical equipment for wound care. This should help a provider comply with regulations which can have a positive effect upon the facility’s ability to earn incentives from Medicaid or other reimbursement sources.

Distribution Channels;
National & Regional
Through a combination of in-house sales representatives, independent sales representatives, strategic authorized distributors, and a national wholesaler, AWT will secure solid market penetration on a regional basis, initially throughout the states of California, New York, Pennsylvania, Massachusetts, Delaware, New Jersey, Maryland, Virginia, District of Columbus, Connecticut, and Illinois. Additional strategic locations will be placed after careful analysis to promote products and services in states renown for; use of progressive technology in health care, high reimbursement rates, and a large and growing elderly population. States such as Texas, Nevada, New Mexico, and Arizona to name a few are certainly candidates.

National Wholesaler
AWT intends to expand its direct marketing efforts with the addition of regional sales directors to interface with the existing supply chain and create strategic alliances offering revenue sharing programs and co-marketing support.

The national wholesales managers will be employees of AWT with incentive compensation commensurate with performance. The regional sales directors will be engaged as employees with compensation and bonus based upon performance.

Additionally, the company will engage LVNA, (Local Visiting Nurses Association) to provide experienced nurses for follow-up, training and monitoring of the installed specialty equipment. AWT is exploring the development of Continuing Education Units (CEU) (for nurses), and Continuing Medical Education (CME) (for doctors), to create additional opportunities to educate the medical community about, as an example - the use of a equipment protocol for the treatment and prevention of decubitus ulcers. The practice of marketing products through education is a time proven method of marketing in the pharmaceutical market.

AWT believes its strategy of offering educational credit will allow it to attract larger audiences at its group presentations at targeted tradeshows.

Strategic authorized distributors
Advanced Wound Technologies will concentrate its sales and marketing efforts on national accounts and large regional healthcare providers and cooperatives, while seeking strategic partners in lower density and rural markets. Advanced Wound Technologies is offering generous revenue sharing arrangements and financed equipment to existing medical supply companies alleviating them the burden of financing, and offering a steady stream of income. The level of revenue share will be dependent upon the level of participation in the delivery, set up and follow-up by the local medical supply company. Acquisition offers may be extended to distributors if the Company feels the sales production and mix of business meets certain specific criteria for AWT.

Independent sales representatives

Advanced Wound Technologies will establish a network of independent sales representatives authorized to sell and distribute all products, associated products and equipment and newly created treatment protocols. Independent sales representatives typically carry other lines of competing and non-competing products. This will extend sales into their existing client bases. The sales reps will provide the necessary staff development and training support to their clients, which will be directed by Advanced Wound Technologies training guidelines. All reps will receive compensation from revenue generated within their respective region and have opportunities for bonus participation for gross production and large account development. Permanent employment or acquisition offers may be extended to as Independent Sales Representative if the Company feels the sales production meets certain criteria for AWT.

International Distribution
Advanced Wound Technologies will establish in 2007, an International Division to sell and distribute all products, associated products and newly created treatment protocols. International sales representatives will carry our line of products as well as other lines of competing and non-competing products for the equipment, appliance, and supply markets. This will maximize sales into the existing client bases with both high and low end cost equipment. Certain of the executive staff of AWT or qualified trainers will provide the necessary staff development and training support to their representatives and clients, which will be directed by Advanced Wound Technologies training guidelines. All International representatives will have opportunities for bonus participation for gross production and large account development. Permanent employment or acquisition offers may be extended to an International Independent Sales Representative or outside Distributor/dealer, if the Company feels the product line and sales production meets certain specific criteria set by and for AWT.


EXPANSION STRATEGY

ACQUISITION STRATEGIES
Business and Operational Characteristics

AWT products add value for customers by improving efficiency, reducing down-time of personnel, bringing new methodologies of treatment, improving quality and performance, reducing costs and helping customers to bring a new level of patient care and healing to healthcare.

The operating companies/divisions of AWT will share the same strategic business characteristics:

focus on specific methodologies and niche applications with direct impact on process performance for end use customers
small, high value added,
process critical equipment standard products built on technology platforms which are customized through high added value applications,
engineering ability to grow the market and capitalize on growth markets
operating culture based on autonomous business units with performance-focused management and high caliber employees.

The way AWT operates creates value for the businesses, creates value for AWT, and creates value for shareholders. A decentralized structure means the management teams in the businesses have real ownership and responsibility and can focus on the priorities. The optimal operational characteristics of the businesses include:

holding leading positions or building positions in niche markets globally
strong, well managed brands and/or products and services internally
multinational customer base, proprietary (if possible) technology with patent portfolio
high gross margins, low capital intensity, and highly cash generative

Acquisition Objectives

AWT is constantly searching for opportunities to add to its portfolio of businesses. Two types of opportunity are given equal priority in this program:

Private or public stand-alone businesses which share the characteristics listed above, and which would operate as autonomous operations within AWT
Opportunities often referred to as bolt-ons, which would be merged with one of our existing businesses to create a stronger and more broadly based growth platform. Such opportunities could be the acquisition of a company, or alternatively a line of business or simply a product line.

We are potentially interested in opportunities that range from early stage businesses which have developed proprietary technology but lack production capabilities and sales and support infrastructure around the world, to divisions of businesses or product groupings which are no longer core to corporate owners and could be merged with one of our existing businesses.

A core focus of the acquisition strategy is a strategic rationale for in-market consolidation for AWT to create, a market leader. The ideal here is to create a Company that can realize benefits within the market by improving pricing and marketing, rationalizing operations and leveraging assets such as technology and skills. We will increase our overall market penetration through capturing scale benefits throughout operations in products and services.

Another area of focus is in licensing proprietary technology which may have been developed for different applications, but could be used in the markets focused on by our operating companies. In this case we either purchase or license intellectual property for use by one of our companies.


Closing Overview

As explained in this document, along with and accompanied by supporting documents, the segment of the health-care field handling wound care/decubitus ulcers is a growing concern for everyone. The ability to bring product that has beneficial results in the healing of serious illness, that reduces costs associated with these illnesses, is a benefit that each and every patient should demand, every healthcare facility should provide, and is a requirement for full payment and Medicare P4P Initiatives.
Advanced Wound Technologies, Inc., intends to deliver a continuous line of innovative and patented medical devises to the healthcare facilities industry, that both maximizes care and provides an opportunity for financial benefit to the provider (either through full reimbursement or incentive payor programs).

AWT began this process by entering the market place as a supplier of a patented wound treatment technology. The Company is currently seeking additional products domestic and internationally, that will strengthen its position and increase its earnings potential. Continuing research and analysis on the newest products available to the industry or through private companies is of our main focus. We expect to bring many unique and highly functional products to the market in the years to come.
πŸ‘οΈ0
CashFXGroupPowerTeam CashFXGroupPowerTeam 17 years ago
Info will be updated near term :)
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock